title: ERBB2 emerges as a new target for colorectal cancer.
abstract: ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.
authors.affiliation: Division of Hematology and Oncology, Beth Israel Deaconess Hospital, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Eirini
authors.initials: E
authors.lastname: Pectasides
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts. Adam_Bass@dfci.harvard.edu.
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Bass
mesh_terms: D000818:Animals; D015179:Colorectal Neoplasms / Q000235:genetics*; D006801:Humans; D009154:Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases